medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2019, Number 1

<< Back Next >>

Ann Hepatol 2019; 18 (1)

Choosing Wisely Canada-Top Five List in Hepatology: Official Position Statement of the Canadian Association for the Study of the Liver (CASL) and Choosing Wisely Canada (CWC)

Brahmania M, Renner EL, Coffin CS, Yoshida EM, Wong P, Zeman M, Shah H

Language: English
References: 28
Page: 165-171
PDF size: 321.12 Kb.


ABSTRACT

Introduction and aim. The prevalence and incidence of chronic liver disease is increasing resulting, in substantial direct and indirect medical costs. Overuse of investigations, treatments and procedures contribute to rising health care costs and can expose patients to unnecessary harm and delay in receiving care. The Choosing Wisely Canada (CWC) campaign has encouraged professional societies to develop statements that are directly actionable by their members in an effort to promote higher-value health care that will lead to downstream effect on how other practitioners make decisions. Material and methods. The Canadian Association for the Study of the Liver (CASL) established its Choosing Wisely top five list of recommendations using the framework put forward by CWC. CASL convened a task force that developed a list of draft recommendations and shared this with CASL membership electronically with eventual ranking of the top five recommendations by consensus at Canadian Digestives Disease Week (CDDW) 2017. Following revisions, the CASL Executive Committee endorsed the final list, which was disseminated online by CWC (July 2017). Results. The top five recommendations physicians and patients should question include: 1) Don’t order serum ammonia to diagnose or manage hepatic encephalopathy (HE). 2) Don’t routinely transfuse fresh frozen plasma, vitamin K, or platelets to reverse abnormal tests of coagulation in patients with cirrhosis prior to abdominal paracentesis, endoscopic variceal band ligation, or any other minor invasive procedures. 3) Don’t order HFE genotyping based on serum ferritin values alone to diagnose hereditary hemochromatosis. 4) Don’t perform computed tomography (CT) or magnetic resonance imaging (MRI) routinely to monitor benign focal liver lesions. 5) Don’t repeat hepatitis C viral load testing in an individual who has established chronic infection, outside of anti-viral treatment. Conclusion. The Choosing Wisely recommendations will foster patient–physician discussions, reduce unnecessary treatment and testing, avert adverse effects from testing and treatment along with reducing medical expenditure in hepatology.


REFERENCES

  1. Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, Srishord M. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clinical Gastroenterology & Hepatology 2011; 9: 524-530.

  2. Murray CJ, Atkinson C, Bhalla K, Birbeck G, Burstein R, Chou D, Dellavalle R, et al. The state of US health, 1990–2010: burden of diseases, injuries, and risk factors. J Am Med Associat 2013; 310: 591-608.

  3. Peery AF, Crockett SD, Barritt AS, Dellon ES, Eluri S, Gangarosa LM, Jensen ET, et al. Burden of Gastrointestinal, Liver, and Pancreatic Diseases in the United States. Gastroenterology 2015; 149: 1731-41.

  4. Kochanek KD, Murphy SL, Xu J, Thejada-Vera B. National Vital Statistics Reports Deaths: Final Data for 2014. 2016. Available from: https://www.cdc.gov/nchs/data/nvsr/nvsr65/ nvsr65_04.pdf.

  5. Udompap P, Kim D, Kim WR. Current and Future Burden of Chronic Nonmalignant Liver Disease. Clin Gastroenterol Hepatol 2015; 13: 2031-41.

  6. Ruhl CE, Sayer B, Byrd-Holt DE, Brown DM. Costs of digestive diseases. The Burden of Digestive Diseases in the United States. NIH publication; 2008, p. 137-43.

  7. Curfman GD, Morrissey S, Drazen JM. High-value health care -a sustainable prop-osition. New Engl J Med 2013; 369: 1163.

  8. Cassel CK, Guest JA. Choosing Wisely Helping Physicians and Patients Make Smart Decisions About Their Care. J Am Med Associat 2012; 307: 1801-2.

  9. Levinson W, Huynh T. Engaging physicians and patients in conversations about un-necessary tests and procedures: Choosing Wisely Canada. Canadian Medical Association Journal 2014; 186: 325-6.

  10. Kanwal F, Kramer JR, Buchanan P, Asch SM, Assioun Y, Bacon BR, Li J, El-Serag HB. The quality of care provided to patients with cirrhosis and ascites in the Department of Veterans Affairs. Gastroenterology 2012; 143: 70-7.

  11. Lockwood AH. Blood ammonia levels and hepatic encephalopathy. Metabolic Brain Disease 2004; 19: 345-49.

  12. Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, Weissenborn K, et al. Hepatic Encephalopathy in Chronic Liver Disease: 2014 Practice Guideline by AASLD and EASL. Hepatology 2014; 60: 715-35.

  13. Nicolao F, Efrati C, Masini A, Merli M, Attili AF, Riggio O. Role of determination of partial pressure of ammonia in cirrhotic patients with and without hepatic encephalo-pathy. J Hepatol 2003; 38: 441-6.

  14. Ong JP, Aggarwal A, Krieger D, Easley KA, Karafa MT, Van Lente F, Arroliga AC, et al. Correlation between ammonia levels and the severity of hepatic encephalopathy. Am J Med 2003; 114: 188-93.

  15. Gundling F, Zelihic E, Seidl H, Haller B, Umgelter A, Schepp W, Dodt C. How to diagnose hepatic encephalopathy in the emergency department. Ann Hepatol 2013; 12: 108-14.

  16. Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy C, Sigal S, et al. Rifaximin treatment in hepatic encephalopathy. New Engl J Med 2010; 362: 1071-81.

  17. Tripodi A, Salerno F, Chantarangkul V, Clerici M, Cazzaniga M, Primignani M, Mannuccio Mannucci P. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005; 41: 553-8.

  18. Tripodi A, Primignani M, Chantarangkul V, Clerici M, Dell’Era A, Fabris F, Salerno F, et al. Thrombin generation in patients with cirrhosis: the role of platelets. Hepatology 2006; 44: 440-5.

  19. Dahlback B. Progress in the understanding of the protein C anticoagulant pathway. Internat J Hematol 2004; 79: 109-16.

  20. Tripodi A, Chantarangkul V, Mannucci PM. Acquired coagulation disorders: revisited using global coagulation/anticoagulation testing. Brit J Haematol 2009; 147: 77-82.

  21. Lisman T, Bongers TN, Adelmeijer J, Janssen HL, de Maat MP, de Groot PG, Leebeek FW. Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006; 44: 53-61.

  22. Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. New Engl J Med 2011; 365: 147-56.

  23. Adams PC, Reboussin DM, Press RD, Barton JC, Acton RT, Moses GC, Leiendecker-Foster C, et al. Biological variability of transferrin saturation and unsaturated iron-binding capacity. Am J Med 2007; 120: e1-e7.

  24. Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS. Diagnosis and Management of hemochromatosis: 2011 practice Guideline by the American Association of for the Study of Liver Disease. Hepatology 2011; 54: 328-34.

  25. Smith-Bindman R, Miglioretti DL, Johnson E, Lee C, Feigelson HS, Flynn M, Greenlee RT. Use of diagnostic imaging studies and associated radiation exposure for patients enrolled in large integrated health care systems, 1996-2010. J Am Med Associat 2012; 307: 2400-9

  26. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.

  27. Marrero JA, Ahn J, Reddy R. ACG Clinical Guideline: The Diagnosis and Manage-ment of Focal Liver Lesions. Am J Gastroenterol 2014; 109; 1328-47.

  28. AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. Available from: http:/www.hcvguidelines.org. Accessed July 26, 2017.




2020     |     www.medigraphic.com